Standard BioTools Inc. – NASDAQ:FLDM
Standard BioTools stock price today
$3.71
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Standard BioTools stock price monthly change
-2.11%
month
Standard BioTools stock price quarterly change
+22.85%
quarter
Standard BioTools stock price yearly change
-19.87%
year
Standard BioTools key metrics
Market Cap | 294.18M |
Enterprise value | 395.80M |
P/E | -4.74 |
EV/Sales | 3.18 |
EV/EBITDA | -3.94 |
Price/Sales | 2.29 |
Price/Book | 12.92 |
PEG ratio | 0.96 |
EPS | -1.36 |
Revenue | 126.76M |
EBITDA | -70.31M |
Income | -89.96M |
Revenue Q/Q | 81.29% |
Revenue Y/Y | 31.27% |
Profit margin | -93.89% |
Oper. margin | -60.86% |
Gross margin | 50.34% |
EBIT margin | -60.86% |
EBITDA margin | -55.47% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeStandard BioTools stock price history
Standard BioTools stock forecast
Standard BioTools financial statements
| Jun 2023 | 27.66M | -17.04M | -61.59% |
|---|---|---|---|
| Sep 2023 | 25.36M | -20.99M | -82.77% |
| Dec 2023 | 28.18M | -19.77M | -70.16% |
| Mar 2024 | 45.54M | -32.15M | -70.61% |
| 2021-08-05 | -0.15 | -0.17 |
|---|---|---|
| 2021-11-08 | -0.22 | -0.18 |
| Jun 2023 | 355827000 | 469.21M | 131.87% |
|---|---|---|---|
| Sep 2023 | 339285000 | 471.00M | 138.82% |
| Dec 2023 | 323067000 | 159.86M | 49.48% |
| Mar 2024 | 777667000 | 200.35M | 25.76% |
| Jun 2023 | -9.32M | 40.12M | -2.08M |
|---|---|---|---|
| Sep 2023 | -11.41M | -49.92M | -1.16M |
| Dec 2023 | -14.06M | -13.11M | -1.00M |
| Mar 2024 | -62.47M | 318.07M | -19.73M |
Standard BioTools alternative data
| Aug 2023 | 615 |
|---|---|
| Sep 2023 | 615 |
| Oct 2023 | 615 |
| Nov 2023 | 615 |
| Dec 2023 | 615 |
| Jan 2024 | 615 |
| Feb 2024 | 615 |
| Mar 2024 | 615 |
| Apr 2024 | 615 |
| May 2024 | 615 |
| Jun 2024 | 615 |
| Jul 2024 | 615 |
Standard BioTools other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2022 | 509573 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CALIGAN PARTNERS LP 10 percent owner | Common Stock | 200,000 | $3.76 | $752,000 | ||
Purchase | CALIGAN PARTNERS LP 10 percent owner | Common Stock | 200,000 | $3.88 | $776,000 | ||
Purchase | CALIGAN PARTNERS LP 10 percent owner | Common Stock, $0.001 par value per share ("Common Stock") | 109,573 | $3.6 | $394,463 | ||
Option | BARTHELEMY NICOLAS director | Stock Option (Right to Buy) | 20,993 | $3.74 | $78,514 | ||
Option | BARTHELEMY NICOLAS director | Common Stock | 20,993 | $3.74 | $78,514 | ||
Option | BARTHELEMY NICOLAS director | Stock Option (Right to Buy) | 5,000 | $3.43 | $17,150 | ||
Option | BARTHELEMY NICOLAS director | Common Stock | 5,000 | $3.43 | $17,150 | ||
Option | KREGER BRADLEY ALLEN officer: SVP, Glo.. | Restricted Stock Units | 3,125 | N/A | N/A | ||
Option | KREGER BRADLEY ALLEN officer: SVP, Glo.. | Restricted Stock Units | 2,391 | N/A | N/A | ||
Option | KREGER BRADLEY ALLEN officer: SVP, Glo.. | Restricted Stock Units | 2,237 | N/A | N/A |
| Patent |
|---|
Application Filling date: 20 Sep 2021 Issue date: 21 Apr 2022 |
Application Filling date: 10 Aug 2021 Issue date: 24 Mar 2022 |
Application Filling date: 28 May 2021 Issue date: 20 Jan 2022 |
Application Filling date: 3 Feb 2021 Issue date: 21 Oct 2021 |
Grant Utility: High-level multiplex amplification Filling date: 16 Dec 2016 Issue date: 14 Sep 2021 |
Application Filling date: 22 Feb 2021 Issue date: 2 Sep 2021 |
Application Filling date: 8 Oct 2020 Issue date: 19 Aug 2021 |
Grant Filling date: 20 Aug 2018 Issue date: 3 Aug 2021 |
Grant Filling date: 10 Dec 2018 Issue date: 23 Mar 2021 |
Application Filling date: 24 Jan 2020 Issue date: 20 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2021 8 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 8 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 9 May 2021 | Q1 2021 Earnings Call Transcript |
| Q4 2020 10 Feb 2021 | Q4 2020 Earnings Call Transcript |
-
What's the price of Standard BioTools stock today?
One share of Standard BioTools stock can currently be purchased for approximately $3.71.
-
When is Standard BioTools's next earnings date?
Unfortunately, Standard BioTools's (FLDM) next earnings date is currently unknown.
-
Does Standard BioTools pay dividends?
No, Standard BioTools does not pay dividends.
-
How much money does Standard BioTools make?
Standard BioTools has a market capitalization of 294.18M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.57% to 106.34M US dollars. Standard BioTools made a loss 74.66M US dollars in net income (profit) last year or -$0.18 on an earnings per share basis.
-
What is Standard BioTools's stock symbol?
Standard BioTools Inc. is traded on the NASDAQ under the ticker symbol "FLDM".
-
What is Standard BioTools's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Standard BioTools?
Shares of Standard BioTools can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Standard BioTools's key executives?
Standard BioTools's management team includes the following people:
- Mr. Stephen Christopher Linthwaite Pres, Chief Executive Officer & Director(age: 52, pay: $1,200,000)
- Mr. Colin McCracken Chief Commercial Officer(age: 52, pay: $734,780)
- Mr. Vikram Jog Chief Financial Officer(age: 69, pay: $667,250)
- Mr. Bradley Allen Kreger Senior Vice President of Global Operations(age: 50, pay: $560,620)
- Mr. Nicholas S. Khadder Senior Vice President, Gen. Counsel & Corporation Sec.(age: 51, pay: $481,580)
-
How many employees does Standard BioTools have?
As Jul 2024, Standard BioTools employs 615 workers.
-
When Standard BioTools went public?
Standard BioTools Inc. is publicly traded company for more then 14 years since IPO on 10 Feb 2011.
-
What is Standard BioTools's official website?
The official website for Standard BioTools is fluidigm.com.
-
Where are Standard BioTools's headquarters?
Standard BioTools is headquartered at 7000 Shoreline Ct Ste 100, South San Francisco, CALIFORNIA.
-
How can i contact Standard BioTools?
Standard BioTools's mailing address is 7000 Shoreline Ct Ste 100, South San Francisco, CALIFORNIA and company can be reached via phone at +1 650 266 6000.
Standard BioTools company profile:
Standard BioTools Inc.
fluidigm.comExchange:
NASDAQ
Full time employees:
615
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
7000 Shoreline Ct Ste 100
South San Francisco, CALIFORNIA 94080
South San Francisco, CALIFORNIA 94080
CIK: 0001162194
ISIN: US34385P1084
CUSIP: 34385P108
